Vol.55 No.4 July 2007
Arbekacin serum pharmacokinetics in patients with malignancies
1)Department of Clinical Laboratory, Bell Land General Hospital, 500-3 Higashiyama, Naka-ku, Sakai, Osaka, Japan
2)Department of Pharmacy, Bell Land General Hospital
Abstract
This study retrospectively evaluated the influence of malignancy on the pharmacokinetics of arbekacin in 20 patients with malignancies (including 14 patients with lung cancers and 6 patients with other malignancies) as compared with that in 36 patients without malignancy. The pharmacokinetic parameters of arbekacin were estimated by the one-compartment model. No differences in arbekacin pharmacokinetics were seen in patients with malignancies as compared with that in those with no malignancy. No differences in arbekacin pharmacokinetics were seen in patients with one type of malignancy as compared with that in those with other types of malignancies. However, significant differences in arbekacin clearance were found between patients with no malignancy and those with lung cancers (0.0648±0.0355 versus 0.0828±0.0281 L/hr/kg [mean±standard deviation], respectively; P<0.05).
Our data suggest that a pharmacokinetic difference exits for arbekacin in patients with lung cancer.
Key word
arbekacin, clearance, lung cancer, pharmacokinetic
Received
December 11, 2006
Accepted
March 23, 2007
Jpn. J. Chemother. 55 (4): 274-277, 2007
